The rise of GLP-1 drugs like Ozempic are changing consumer food waste patterns both at home and in restaurant settings.

Wockhardt will deepen its novel antibiotics pipeline over the next five years and focus on building a biosimilar business for ...

New York’s reputation as a trailblazer for health equity is in danger. We must ensure equity in obesity treatment.

Linda Bethea details how the marketer of brands including Oikos and Silk is approaching artificial intelligence and emerging ...

The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Contrave and Wegovy are both weight loss medications. Learn about their effectiveness, side effects, costs, and which ...

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...